Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 292, Issue 5, 2007, Pages

  Watts, Stephanie W ^a   Rondelli, Catherine ^a   Thakali, Keshari ^a   Li, Xiaopeng ^b   Uhal, Bruce ^b   Pervaiz, Mohammad H ^a   Watson, Ralph E ^a   Fink, Gregory D ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Artery; Matrix metalloproteinase; Vein

Indexed keywords

DEOXYCORTICOSTERONE ACETATE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14; SODIUM CHLORIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; DEOXYCORTICOSTERONE; MATRIX METALLOPROTEINASE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CAVA VEIN; CHEMICAL ANALYSIS; CONTROLLED STUDY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; MALE; MORPHOLOGY; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING; ZYMOGRAPHY; ADAPTATION; ANIMAL; CELL SIZE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; THORACIC AORTA;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; AORTA, THORACIC; CELL SIZE; DESOXYCORTICOSTERONE; HYPERTENSION; MALE; MATRIX METALLOPROTEINASES; RATS; RATS, SPRAGUE-DAWLEY; SODIUM CHLORIDE; VENAE CAVAE;

EID: 34250796742     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00900.2006     Document Type: Article

References (58)

1. Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ETA receptors. Hypertension 39: 679-684, 2002.
2. Asanuma K, Magid R, Johnson C, Nerem RM, Galis ZS. Uniaxial strain upregulates matrix-degrading enzymes produced by human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 284: H1778-H1784, 2003.
3. Banerji A, Chakraborti J, Mitra A, Chatterjee A. Cell membrane-associated MT1-MMP-dependent activation of pro-MMP-2 in A375 melanoma cells. J Environ Pathol Toxicol Oncol 24: 3-17, 2005.
4. Bergan JJ, Schmid-Schonbein GW, Coleridge Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Chronic venous disease. N Engl J Med 355: 488-498, 2006.
5. Bobik A, Tkachuk V. Metalloproteinases and plasminogen activators in vessel remodeling. Curr Hypertens Rep 5: 466-472, 2003.
6. Bouvet C, Gilbert LA, Girardot D, de Blois D, Moreau P. Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 45: 432-437, 2005.
7. Camp TM, Smiley LM, Hayden MR, Tyagi SC. Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats. J Hypertens 21: 1719-1727, 2003.
8. Carretero OA. Vascular remodeling and the kallikrein-kinin system. J Clin Invest 115: 588-591, 2005.
9. Chan V, Hoey A, Brown L. Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats. Br J Pharmacol 148: 902-908, 2006.
10. Chesler N, Ku D, Galis ZS. Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo. Am J Physiol Heart Circ Physiol 277: H2002-H2009, 1999.
11. Choy JS, Dang Q, Molloi S, Kassab GS. Nonuniformity of axial and circumferential remodeling of large coronary veins in response to ligation. Am J Physiol Heart Circ Physiol 290: H1558-H1565, 2006.
12. Choy JS, Kassab GS. A novel strategy for increasing wall thickness of coronary venules prior to retroperfusion. Am J Physiol Heart Circ Physiol 291: H972-H978, 2006.
13. Chun TH, Sabeh F, Ota I, Murphy H, McDonagh KT, Holmbeck K, et al. MT1-MMP-dependent neovessels formation within the confines of the three-dimensional extracellular matrix. J Cell Biol 167: 757-767, 2004.
14. Cox RH. Time course of arterial wall changes with DOCA plus salt hypertension in the rat. Hypertension 4: 27-38, 1982.
15. Deatrick KB, Eliason JL, Lynch EM, Moore AJ, Dewyer NA, Varma MR, Pearce CG, Upchurch GR, Wakefield TW, Henke PK. Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model. J Vasc Surg 42: 140-148, 2005.
16. De Kleijn DP, Sluijter JP, Smit J, Velema E, Richard W, Schoneveld AH, et al. Furin and membrane type-1 metalloproteinase mRNA levels and activation of metalloproteinase-2 are associated with arterial remodeling. FEBS Lett 501: 37-41, 2001.
17. Ergul A, Portik-Dobos V, Giulumian AD, Molero MM, Fuchs LC. Stress upregulation of arterial matrix metalloproteinase expression and activity via endothelin A receptor activation. Am J Physiol Heart Circ Physiol 285: H2225-H2232, 2003.
18. Fenning A, Harrison G, Rose'meyer R, Hoey A, Brown L. L-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 289: H1408-H1416, 2005.
19. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85: 906-911, 1999.
20. Fernandez-Patron C, Radomski, Davidge ST. Role of matrix metalloproteinase-2 in thrombin-induced vasorelaxation of rat mesenteric arteries. Am J Physiol Heart Circ Physiol 278: H1473-H1479, 2000.
21. Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 87: 670-676, 2000.
22. Filippov S, Koenig GC, Chun TH, Hotary KB, Ota I, Bugge TH, Roberts JD, Fay WP, Birkedal-Hansen H, Holmbeck K, Sabeh F, Allen ED, Weiss SJ. MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells. J Exp Med 202: 663-671, 2005.
23. Fink GD, Johnson RJ, Galligan JJ. Mechanisms of increased venous smooth muscle tone in deoxycorticosterone acetate salt hypertension. Hypertension 35: 464-469, 2000.
24. Fridman R, Toth M, Chvyrkova I, Meroueh SO, Mobashery S. Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev 22: 153-166, 2003.
25. Galli A, Svegliati-Baroni G, Ceni E, Milani S, Ridolfi F, Salzano R, Tarocchi M, Grappone C, Pellegrini G, Benedetti A, Surrenti C, Casini A. Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology 41: 1074-1084, 2005.
26. Grote K, Flach I, Luchtefeld M, Akin E, Holland SM, Drexler H, Schieffer B. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NADPH oxidase-derived reactive oxygen species. Circ Res 92: e80-e86, 2003.
27. Gusic RJ, Myung R, Petko M, Gaynor JW, Gooch KJ. Shear stress and pressure modulate saphenous vein remodeling ex vivo. J Biochem (Tokyo) 38: 1760-1769, 2005.
28. Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor. Circ Res 94: 68-76, 2004.
29. Hayashi K, Mori K, Miyazaki H. Biomechanical response of femoral vein to chronic elevation of blood pressure in rabbits. Am J Physiol Heart Circ Physiol 284: H511-H518, 2003.
30. Hayden MR, Sowers JR, Tyagi SC. The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded. Cardiovasc Diabetol 4: 9, 2005.
31. He JZ, Quan A, Xu Y, Teoh H, Wang G, Fish JE, Steer BM, Itohara S, Marsden PA, Davidge ST, Ward ME. Induction of matrix metalloproteinase-2 enhances systemic vasoconstriction after hypoxia. Am J Physiol Heart Circ Physiol 292: H684-H693, 2007.
32. Henke PK, Varma MR, Deatrick KB, Dewyer NA, Lynch EM, Moore AJ, Dubay DA, Sukheepod P, Pearce CG, Upchurch GR, Kunkel SL, Franz MG, Wakefield TW. Neutrophils modulate post-thrombotic vein wall remodeling but not thrombus neovascularization. Thromb Haemost 95: 272-281, 2006.
33. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation and fibrosis. Hypertension 38: 581-587, 2001.
34. Jacob MP, Badier-Commander C, Fontaine V, Benazzoug Y, Feldman L, Michel JB. Extracellular matrix remodeling in the vascular wall. Pathol Biol (Paris) 49: 326-332, 2001.
35. Johar S, Cave AC, Naravanapanicker A, Grieve DJ, Shah AM. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J 20: 1546-1548, 2006.
36. Johnson RJ, Galligan JJ, Fink GD. Effect of an ETB selective and a mixed ETA/B endothelin receptor antagonist on venomotor tone in deoxycorticosterone-salt hypertension. J Hypertens 19: 431-440, 2001.
37. Karam H, Heudes D, Gonzales MF, Loffler BM, Clozel M, Clozel JP. Respective role of humoral factors and blood pressures in aortic remodeling of DOCA hypertensive rats. Am J Hypertens 9: 991-998, 1996.
38. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F. Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 24: 195-204, 1994.
39. Lehoux S, Lemarie CA, Esposito B, Lijnen HR, Tedguis A. Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation 109: 1041-1047, 2004.
40. Lepetit H, Eddahibi S, Fadel E, Frisdal E, Munaut C, Noel A, Humbert M, Adnot S, D'Ortho MP, Lafuma C. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J 25: 834-842, 2005.
41. Mark AL. Structural changes in resistance and capacitance vessels in borderline hypertension. Hypertension 6 Suppl III: 69-73, 1984.
42. Martinez A, Oh HR, Unsworth EJ, Bregonzio C, Saavedra JM, Stetler-Stevenson WG, Cuttitta F. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 383: 413-418, 2004.
43. Millette E, Demeilliers B, Wu R, Laplante MA, El Midaoui A, Moreau P, Lamontagne D, de Champlain J. Comparison of the cardiovascular protection by omapatrilat and lisinopril treatments in DOCA-salt hypertension. J Hypertens 21: 125-135, 2003.
44. Monos E, Contney SJ, Cowley AW, Stekiel WJ. Effect of long-term tilt on mechanical and electrical properties of rat saphenous vein. Am J Physiol Heart Circ Physiol 256: H1185-H1191, 1989.
45. Monos E, Kauser K, Contney SJ, Cowley AW, Stekiel WJ. Biomechanical and electrical responses of normal and hypertensive veins to short-term pressure increases. In: Cellular Aspects of Hypertension, edited by Bruschi G and Borghetti A. Berlin: Springer-Verlag, 1991, p. 51-57.
46. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPS. Cardiovasc Res 69: 562-573, 2006.
47. O'Callaghan CJ, Williams B. Mechanical strain-induced extracellular matrix production by human vascular smooth muscle cells: role of TGF-1. Hypertension 36: 319-324, 2000.
48. Pascarella L, Penn A, Schmid-Schonbein GW. Venous hypertension and the inflammatory cascade: major manifestations and trigger mechanisms. Angiology 56 Suppl 1: S3-S10, 2005.
49. Pascarella L, Schmid-Schonbein GW, Bargan J. An animal model of venous hypertension: the role of inflammation in venous valve failure. J Vasc Surg 41: 303-311, 2005.
50. Rizzoni D, Rossi GP, Porteri E, Sticchi D, Rodella L, Rezzani R, Sleiman I, De Ciuceis C, Paiardi S, Bianchi R, Nussdorfer GG, Agabiti-Rose E. Bradykinin and matrix metalloproteinases are involved with the structural alterations of rat small resistance arteries with inhibition of ACE and NEP. J Hypertens 22: 759-766, 2004.
51. Ruiz V, Ordonez RM, Berumen J, Ramirez R, Uhal B, Becerril C, Pardo A, Selman M. Unbalanced collagenases/TIMP-1 expression and epithelial apoptosis in experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol 285: L1026-L1036, 2003.
52. Safar ME, Laurent P. Pulse pressure and arterial stiffness in rats: comparison with humans. Am J Physiol Heart Circ Physiol 285: H1363-H1369, 2003.
53. Sharony R, Pintucci G, Saunders PC, Grossi EA, Baumann FG, Galloway AC, Mignatti P. Matrix metalloproteinase expression in vein grafts: role of inflammatory mediators and extracellular signal regulated kinases-1 and -2. Am J Physiol Heart Circ Physiol 290: H1651-H1659, 2006.
54. Sudhir K, Angus JA, Esler MD, Jennings GL, Lambert GW, Korner PI. Altered venous responses to vasoconstrictor agonists and nerve stimulation in human primary hypertension. J Hypertens 8: 1119-1128, 1990.
55. Takase S, Pascarella L, Bergan JJ, Schmid-Schonbein GW. Hypertension-induced venous valve remodeling. J Vasc Surg 39: 1329-1333, 2004.
56. Watts SW, Fink GD, Northcott CA, Galligan JJ. Endothelin-1-induced venous contraction is maintained in DOCA-salt hypertension: studies with receptor agonists. Br J Pharmacol 137: 69-79, 2002.
57. Woessner JF. The determination of hydroxyproline in tissue and protein samples containing small proportions of this amino acid. Arch Biochem Biophys 93: 440-447, 1961.
58. Yasmin Wallace S, McEniery CM, Dakham Z, Pusalkar P, Maki-Petaja K, Ashby MJ, Cockcroft JR, Wilkinson IB. Matrix metalloproteinase-9 (MMP-9), MMP-2 and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 25: 372-378, 2005.